Skip to main content

Roflumilast

Also known as: Daliresp, Daxas, 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide, 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide, B 9302-107, BY 217, BYK 20869, Roflost, Roster, CS-1960, APTA 2217

Roflumilast (CAS 162401-32-3) is a compound in the Organohalogen Compounds category listed in the Jingsj chemical database. It has the molecular formula C17H14Cl2F2N2O3 and a molecular weight of 403.207 g/mol. Key properties include a melting point of 158°C, a boiling point of 430.6±45.0 °C at 760 mmHg, a density of 1.5±0.1 g/cm3 and a flash point of 214.2±28.7 °C. It is classified under GHS with signal word Warning and hazard statements H315 — Causes skin irritation, H319 — Causes serious eye irritation and H335 — May cause respiratory irritation. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.
162401-32-3
Jingsj CID
J-1970767-7
Molecular Formula
C17H14Cl2F2N2O3
Molecular Weight
403.207 g/mol
Category
Organohalogen Compounds
Last updated
8/21/2026

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point158°C
Boiling Point430.6±45.0 °C at 760 mmHg
Density1.5±0.1 g/cm3
Flash Point214.2±28.7 °C
Exact Mass402.034943
PSA60.45000
LogP4.84
Vapor Pressure0.0±1.0 mmHg at 25°C
Refractive Index1.604
Storage ConditionsRefrigerator

GHS Safety & Compliance

IrritantSignal word: Warning
  • H315 — Causes skin irritation
  • H319 — Causes serious eye irritation
  • H335 — May cause respiratory irritation

Activity & Biological Data

TargetIC50: 0.7 nM (PDE4A1), 0.9 nM (PDE4A4), 0.7 nM (PDE4B1), 0.2 nM (PDE4B2)[1]
Additional Information[1]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [2]. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. [3]. Hatzelmann A, et al. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr;297(1):267-79. [4]. Richmond BW, et al. Airway bacteria drive a progressive COPD-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat Commun. 2016 Apr 5;7:11240. [5]. Ding H, et al. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol. 2017 Jul 29.

Frequently Asked Questions

What is the CAS number of Roflumilast?

The CAS number of Roflumilast is 162401-32-3.

What are the molecular formula and molecular weight of Roflumilast?

Roflumilast has molecular formula C17H14Cl2F2N2O3 and molecular weight 403.207 g/mol.

Is Roflumilast hazardous?

Roflumilast has GHS signal word Warning and hazard statements H315 — Causes skin irritation; H319 — Causes serious eye irritation; H335 — May cause respiratory irritation.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated:

How to cite: Jingsj. "Roflumilast (CAS 162401-32-3)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1970767-7 (accessed 2026-11-06).

Data for reference only; verify product details with suppliers before purchase.